Sign inJoin waitlistJoin the waitlist

Carlos Barcenas

Associate Medical Director, Breast Cancer Survivorship · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

Breast Cancer Survivorship · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2010–2013
Internal Medicine
Medical College of Georgia
2006–2009
Occupational Health
1993–1997
Doctor of Medicine
1988–1992

Research

Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery
JAMA Surgery · 2017 · 179 citations
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Journal of Clinical Oncology · 2020 · 173 citations
Effects of nativity, age at migration, and acculturation on smoking among adult Houston residents of Mexican descent
American Journal of Public Health · 2005 · 145 citations

Vicente Valero
20 papers
Sharon Giordano
14 papers
Benjamin Smith
12 papers
Henry Kuerer
12 papers · 1 as a resident
Elizabeth Mittendorf
10 papers
Gabriel Hortobagyi
10 papers
Mariana Mac Gregor
10 papers
Naoto Ueno
10 papers
Rashmi Murthy
10 papers
DT
Debasish Tripathy
9 papers
Banu Arun
8 papers
Kelly Hunt
8 papers

Clinical trials

Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)
Principal investigator · Withdrawn
M.D. Anderson Cancer Center
2026
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2019–2023
Circulating Tumor DNA
Site PI · Recruiting · Phase 2
Yale University
2025–2027
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Site PI · Recruiting · Phase 3
Stemline Therapeutics, Inc.
2024–2032